Hypertension
📧 Sign up to get email alerts when something new happens for Hypertension.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-07-17FDA Approved: FUROSEMIDE — Original Application (Aurobindo Pharma Limited)
FDA approves Aurobindo Pharma Limited's original ANDA for furosemide, a generic loop diuretic. The approval covers the generic product for i…
-
FDA approval · 2025-07-17FDA Approved: HYDRALAZINE HYDROCHLORIDE — Original Application (Baxter Healthcare Corporation)
FDA approves the Hydralazine hydrochloride original application from Baxter Healthcare Corporation, granting generic approval for the treatm…
-
FDA approval · 2025-07-10FDA Approved: DILTIAZEM HYDROCHLORIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for diltiazem hydrochloride (generic) from Sun Pharmaceutical Industries, Inc. under an ANDA. This a…
-
FDA approval · 2025-07-02FDA Approved: DILTIAZEM HYDROCHLORIDE — Original Application (Ingenus Pharmaceuticals, LLC)
FDA approved a generic diltiazem hydrochloride product from Ingenus Pharmaceuticals under an Original Application (ANDA), expanding access t…
-
FDA approval · 2025-06-25FDA Approved: NICARDIPINE HYDROCHLORIDE — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approved NICARDIPINE HYDROCHLORIDE as a generic product under an Original Application (ANDA) from Zydus Pharmaceuticals USA Inc. This co…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-06-24EMA Authorised: Tolucombi (telmisartan;hydrochlorothiazide) — Krka, d.d., Novo mesto
The European Medicines Agency has authorized Tolucombi, a fixed-dose combination tablet of telmisartan and hydrochlorothiazide, for the trea…
-
FDA approval · 2025-06-24FDA Approved: CARVEDILOL PHOSPHATE — Supplemental Application (AvKARE)
FDA approved a supplemental application for carvedilol phosphate submitted by AvKARE. This action approves a generic carvedilol phosphate pr…
-
FDA approval · 2025-06-20FDA Approved: METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for Sun Pharmaceutical's Metoprolol Tartrate and Hydrochlorothiazide, enabling the marketing of the …
-
FDA approval · 2025-06-20FDA Approved: HYZAAR — Supplemental Application (Organon LLC)
FDA approved a supplemental application for HYZAAR (losartan potassium and hydrochlorothiazide) from Organon LLC.
-
FDA approval · 2025-06-17FDA Approved: CLONIDINE TRANSDERMAL SYSTEM — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for the Clonidine Transdermal System (clonidine patch) from Actavis Pharma, Inc., marking regulatory…
-
FDA approval · 2025-06-11FDA Approved: METOPROLOL TARTRATE — Supplemental Application (Hospira, Inc.)
FDA approved a supplemental application for metoprolol tartrate (Hospira, Inc.), a generic beta-blocker, confirming continued approval of th…
-
FDA approval · 2025-06-06FDA Approved: LABETALOL HYDROCHLORIDE — Supplemental Application (Advagen Pharma Ltd)
FDA approves Advagen Pharma Ltd's supplemental application for labetalol hydrochloride (generic), updating the product's regulatory status.
-
FDA approval · 2025-06-05FDA Approved: WIDAPLIK — Original Application (Azurity Pharmaceuticals, Inc.)
WIDAPLIK received FDA approval as an original NDA for a fixed-dose combination of telmisartan, amlodipine, and indapamide for the treatment …
-
FDA approval · 2025-06-05FDA Approved: VALSARTAN — Original Application (Advagen Pharma Ltd)
FDA approved the original application for a generic valsartan oral tablet from Advagen Pharma Ltd.
-
FDA approval · 2025-06-02FDA Approved: HYDRALAZINE HYDROCHLORIDE — Original Application (Meitheal Pharmaceuticals Inc.)
FDA approves the Original Application for Hydralazine hydrochloride as a generic product by Meitheal Pharmaceuticals Inc.
-
FDA approval · 2025-05-23FDA Approved: AMLODIPINE AND ATORVASTATIN — Supplemental Application (Apotex Corp.)
FDA approved a supplemental abbreviated new drug application (ANDA) for Apotex Corp. to market a generic fixed-dose combination of amlodipin…
-
EMA approval · 2025-05-23EMA Authorised: Ifirmasta (previously Irbesartan Krka) (irbesartan hydrochloride) — Krka, d.d., Novo mesto
EMA has authorised Ifirmasta (irbesartan hydrochloride) by Krka for the treatment of hypertension. It is an authorised generic version of ir…
-
FDA approval · 2025-05-22FDA Approved: AMLODIPINE AND ATORVASTATIN — Original Application (Alembic Pharmaceuticals Inc.)
FDA approves Alembic Pharmaceuticals' fixed-dose combination of amlodipine and atorvastatin under an original ANDA application.
-
FDA approval · 2025-05-14FDA Approved: OLMESARTAN MEDOXOMIL AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE — Original Application (Slate Run Pharmaceuticals, LLC)
The FDA approved Slate Run Pharmaceuticals' generic fixed-dose combination of olmesartan medoxomil, amlodipine besylate, and hydrochlorothia…
-
FDA approval · 2025-05-09FDA Approved: NICARDIPINE HYDROCHLORIDE — Supplemental Application (Lifestar Pharma LLC)
FDA approved a supplemental application for nicardipine hydrochloride from Lifestar Pharma LLC, indicating a change under an approved ANDA.
-
FDA approval · 2025-05-08FDA Approved: FUROSEMIDE — Supplemental Application (Eugia US LLC)
FDA approved a supplemental application for furosemide by Eugia US LLC under an ANDA, confirming approval of the supplement.
-
FDA approval · 2025-05-06FDA Approved: DILTIAZEM HYDROCHLORIDE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for diltiazem hydrochloride from Mylan Pharmaceuticals Inc., enabling continued marketing of the…
-
EMA approval · 2025-04-28EMA Authorised: Twynsta (telmisartan;amlodipine) — Boehringer Ingelheim International GmbH
The EMA authorised Twynsta, a fixed-dose combination of telmisartan and amlodipine, for the treatment of hypertension. The decision was made…
-
EMA approval · 2025-04-23EMA Authorised: Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG) (telmisartan) — Bayer AG
EMA authorised Kinzalmono, a telmisartan product, by Bayer AG for the treatment of hypertension.
-
EMA approval · 2025-04-23EMA Authorised: Pritor (telmisartan) — Bayer AG
The EMA authorised the marketing of Pritor (telmisartan) by Bayer AG for the treatment of hypertension.